Krystal Biotech KRYS 深 沪
等待开盘 11-06 09:30:00 美东时间
200.745
-2.515
-1.24%
华盛通- 最 高204.04
- 今 开198.375
- 成交量 57.81万股
- 最 低 194.915
- 昨 收 203.26
- 总市值 58.10亿
- 52周最高 212.98
- 市盈率 静 66.96
- 换手率 2.00%
- 52周最低 122.80
- 委 比 89.81%
- 总股本 2894.30万
- 历史最高 219.34
- 量 比 1.20
- 振 幅 4.49%
- 历史最低 8.03
- 每 手 1
- 风险率 19.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
Chardan Capital Maintains Buy on Krystal Biotech, Raises Price Target to $220
Chardan Capital analyst Geulah Livshits maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $216 to $220.
11-04 21:23
Krystal Biotech Q3 EPS $2.66 Beats $1.03 Estimate, Sales $97.800M Beat $93.186M Estimate
Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $2.66 per share which beat the analyst consensus estimate of $1.03 by 158.5 percent. This is a 192.31 percent increase over earnings of $0.91 per share from
11-03 20:01
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
Earnings Preview For TG Therapeutics
TG Therapeutics (NASDAQ:TGTX) will release its quarterly earnings report on Mon...
11-01 03:01
Krystal Biotech Unit Launches VYJUVEK In Japan For Treatment Of Dystrophic Epidermolysis Bullosa; VYJUVEK Priced At ¥2,955,232.7 Per Unit In Japan
Krystal Biotech, Inc. today reported that, effective as of October 22, 2025, its wholly owned subsidiary, Krystal Biotech Japan KK, commenced the commercial launch of VYJUVEK® (beremagene geperpavec) in Japan for
10-22 21:14
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
快讯 | Krystal Biotech Inc：美国银行环球研究将目标价从182美元上调至255美元
Krystal Biotech Inc : BofA Global Research Raises Price Objective to $255 From ...
10-17 18:29
Krystal Biotech Says It Gets US FDA's Platform Technology Designation For HSV-1 Viral Vector To Treat Neurotrophic Keratitis
PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology designation to the
10-14 20:09
Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis
Krystal Biotech announced that the FDA granted platform technology designation to its genetically modified HSV-1 viral vector used in KB801, a redosable eye drop gene therapy for treating neurotrophic keratitis. This designation recognizes the reproducibility and scalability of their HSV-1 platform and may help accelerate future product development. KB801 aims to reduce treatment burden by enabling sustained NGF production in the eye, with its sa...
10-14 12:00
